Company Outline
Overview information
| Corporate philosophy | With passion and exceptional technologies, experts in CMC research support the creation of outstanding and innovative drugs.SPERA PHARMA was established as a spin-out of Takeda Pharmaceutical Company by Chemistry, Manufacturing and Controls (CMC) research experts, who were already responsible for delivering numerous new drugs to high global acclaim. As a member of the Bushu Pharmaceuticals Group, SPERA PHARMA is responsible for the entire CMC process, from R&D through application; it provides services that meet the needs of customers. As the development of new drugs becomes increasingly difficult, SPERA PHARMA will hone technologies it has fostered and refined, advancing the research and development of promising drugs, and helping to achieve an even healthier society through the creation of outstanding new drugs. |
|---|---|
| Business Started | July 1st, 2017 |
| Capital | 310 million yen |
| Representative | Toshio Yoshioka, President |
| Address | 17-85 Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-0024, Japan |
| Business | Pharmaceuticals Contract R&D and Manufacturing |
| Directors and Officers | Directors：Jun Yokohama, Toshio Yoshioka, Tetsuya Morikawa, Hidenori Tamura Auditor：Yasuhiko Fujiu Corporate Adviser：Katsuhiko Hatazawa |
Access
Access to head office
From JR Osaka Station
Walk from JR Osaka station to Hankyu Umeda station, and take a Hankyu train from Umeda station to Juso station. About 5-minute walk from Juso Station
From Shin-Osaka Station
Walk from Shin-Osaka Station to Nishinakajima-Minamikata Station of Osaka subway-Midosuji Line, and take a train to Hankyu Minamikata Station. Transfer to Hankyu-line to Hankyu Juso station. About 5-minute walk from Juso Station
From Osaka International Airport
Take an Osaka-monorail from Osaka International Airport to Hotarugaike Station, and transfer to Hankyu line to Hankyu Juso Station. About 5-minute walk from Juso Station
Organization
September, 2018
SPERA provides CMC solutions from early-stage through new drug application